查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585630

生物同質激素市場：按產品類型、荷爾蒙類型、最終用戶分類 - 全球預測 2025-2030

Bioidentical Hormones Market by Product (Creams & Gels, Injectable, Patches & Implants), Hormones Type (Estrogens, Progesterone, Testosterone), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年生物同質激素市場價值為4.9345億美元，預計到2024年將達到6.1646億美元，複合年成長率為25.02%，預計到2030年將達到23.5601億美元。

生物同質激素被定義為分子結構與人體自然產生的荷爾蒙相似的人工激素，在治療更年期、甲狀腺疾病和荷爾蒙失衡等疾病方面具有顯著的用途。其主要最終用途包括診所、醫院和私人藥房的治療應用。市場成長受到人們對天然和客製化荷爾蒙補充療法日益成長的認知和需求的影響。隨著世界老化，對生物同質激素的需求不斷增加，以對抗與老齡化相關的荷爾蒙下降。此外，複合藥局的技術進步正在實現個人化解決方案，進一步推動市場擴張。擴大宣傳宣傳活動，教育消費者了解生物同質激素的功效和安全性是一個潛在的機會。此外，與醫療保健提供者建立策略聯盟和合作可以顯著提高市場滲透率。由於都市化和醫療保健機會的增加，亞洲和拉丁美洲的新興市場提供了充足的成長機會。

主要市場統計
基準年[2023] 4.9345億美元
預測年份 [2024] 61646萬美元
預測年份 [2030] 23.5601億美元
複合年成長率（%） 25.02%

然而，市場面臨重大限制和挑戰，例如缺乏監管和標準化臨床測試，這可能會影響公眾認知並阻礙成長。此外，替代治療方法的可用性以及衛生相關人員對其有效性的懷疑可能會阻礙其採用。業務成長的創新領域包括研究生物同質激素的新輸送系統以及開發綜合性患者教育平台以消除誤解並加強信任。生物同質激素與其他藥物的相互作用還有進一步研究的空間，這可能為更安全、更有效的聯合治療打開大門。

生物同質激素市場的特徵是其動態性，受到持續的科學研究和醫學趨勢的推動。投資研究和開發穩定情緒或增強認知功能的生物同質配方的公司可能會佔據重要的市場佔有率。對於尋求在不斷變化的市場格局中建立主導地位的公司來說，透明的傳播策略和對基於證據的效益的關注至關重要。

市場動態：揭示快速發展的生物同質激素市場的關鍵市場洞察

供需的動態交互作用正在改變生物同質激素市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 增加荷爾蒙缺乏症篩檢
    • 人群中荷爾蒙缺乏症的盛行率
    • 老年人口增加
  • 市場限制因素
    • 各種副作用，包括視力模糊以及乳癌和心臟病的風險
  • 市場機會
    • 已開發國家主要研究公司集中
    • 為特定患者客製化荷爾蒙療法配方
  • 市場問題
    • 與合成荷爾蒙產品相比，產品純度和安全性方面的品管不足

波特的五力：駕馭生物同質荷爾蒙市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解生物同質荷爾蒙市場的外部影響

外部宏觀環境因素在塑造生物同質荷爾蒙市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解生物同質荷爾蒙市場的競爭格局

對生物同質激素市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣生物同質荷爾蒙市場供應商的績效評估

FPNV定位矩陣是評估生物同質荷爾蒙市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製生物同質荷爾蒙市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對生物同質激素市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 增加荷爾蒙缺乏檢測
      • 人群中荷爾蒙缺乏症的盛行率
      • 老年人口增加
    • 抑制因素
      • 它有多種副作用，包括視力喪失以及乳癌和心臟病的風險。
    • 機會
      • 已開發國家主要研究公司集中
      • 為特定患者客製化荷爾蒙療法配方
    • 任務
      • 與合成荷爾蒙產品相比，產品純度和安全性方面的品管不足
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章生物同質荷爾蒙市場：依產品

  • 介紹
  • 霜和凝膠
  • 注射
  • 貼片和植入
  • 錠劑和膠囊

第7章生物同質激素市場：依激素類型

  • 介紹
  • 雌激素
  • 黃體酮
  • 睪固酮

第8章生物同質激素市場：依最終用戶分類

  • 介紹
  • 學術研究所
  • 醫院/診所

第9章美洲生物同質荷爾蒙市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太生物同質荷爾蒙市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲生物同質荷爾蒙市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Bayers AG
  • BIoTe Medical, LLC
  • Defy Medical, LLC
  • Full Life Wellness Center
  • Merck KGaA
  • NextGenRx Compounding Pharmacy
  • Novartis AG
  • Noven Pharmaceuticals, Inc. Hisamitsu Group
  • Novo Nordisk A/S
  • Nueva Aesthetics
  • Optimal Health and Wellness
  • Pavilion Compounding Pharmacy, LLC
  • Pellecome, LLC
  • Pfizer Inc.
  • Schwietermans Pharmacy
  • The Biostation
  • TherapeuticsMD, Inc.
Product Code: MRR-431C35F6C1E4

The Bioidentical Hormones Market was valued at USD 493.45 million in 2023, expected to reach USD 616.46 million in 2024, and is projected to grow at a CAGR of 25.02%, to USD 2,356.01 million by 2030.

Bioidentical hormones, defined as man-made hormones similar to the ones naturally produced by the human body in molecular structure, have notable necessity and applications in treating conditions like menopause, thyroid disorders, and hormonal imbalances. Their primary end-use scopes span across therapeutic applications in clinics, hospitals, and individual pharmacies. The market's growth is influenced by increasing awareness and demand for natural and tailored hormone replacement therapies. With an aging global population, there is a heightened demand for bioidentical hormones to address age-related hormone declines. Additionally, technological advancements in compounding pharmacies allow for personalized solutions, further fueling market expansion. Potential opportunities lie in expanding awareness campaigns to educate consumers on bioidentical hormone efficacy and safety. Furthermore, forming strategic alliances and collaborations with healthcare providers can significantly enhance market penetration. Emerging markets in Asia and Latin America present ample growth opportunities, driven by increasing urbanization and healthcare access.

KEY MARKET STATISTICS
Base Year [2023] USD 493.45 million
Estimated Year [2024] USD 616.46 million
Forecast Year [2030] USD 2,356.01 million
CAGR (%) 25.02%

However, the market faces significant limitations and challenges, including regulatory scrutiny and a lack of standardized clinical trials, which can affect public perception and hinder growth. Moreover, the availability of alternative treatments and skepticism among medical professionals regarding efficacy can pose barriers to widespread adoption. Innovative areas for business growth include research into novel delivery systems for bioidentical hormones and the development of comprehensive patient education platforms to dispel misconceptions and reinforce trust. There is also room for further research into bioidentical hormone interactions with other medications, which could open doors to safer and more effective combination therapies.

The bioidentical hormone market is characterized by its dynamic nature, driven by continuous scientific research and healthcare trends. Companies investing in R&D for enhanced bioidentical formulations capable of stabilizing mood or boosting cognitive functions could capture significant market share. Focusing on transparent communication strategies and evidence-based benefits will be crucial for businesses seeking to establish a leadership position in this evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bioidentical Hormones Market

The Bioidentical Hormones Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing screening for hormonal deficiency
    • Prevalence of hormonal deficiency in the population
    • Rise in geriatric population
  • Market Restraints
    • Varying side effects such as blurred vision or risk of breast cancer and heart attack
  • Market Opportunities
    • Concentration of major research companies in the developed countries
    • Formulation of customized hormonal therapy for specific patients
  • Market Challenges
    • Lack of quality control on purity and safety of the product compared to synthetic hormone products

Porter's Five Forces: A Strategic Tool for Navigating the Bioidentical Hormones Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bioidentical Hormones Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bioidentical Hormones Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bioidentical Hormones Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bioidentical Hormones Market

A detailed market share analysis in the Bioidentical Hormones Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bioidentical Hormones Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bioidentical Hormones Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bioidentical Hormones Market

A strategic analysis of the Bioidentical Hormones Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bioidentical Hormones Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bayers AG, Biote Medical, LLC, Defy Medical, LLC, Full Life Wellness Center, Merck KGaA, NextGenRx Compounding Pharmacy, Novartis AG, Noven Pharmaceuticals, Inc. Hisamitsu Group, Novo Nordisk A/S, Nueva Aesthetics, Optimal Health and Wellness, Pavilion Compounding Pharmacy, LLC, Pellecome, LLC, Pfizer Inc., Schwietermans Pharmacy, The Biostation, and TherapeuticsMD, Inc..

Market Segmentation & Coverage

This research report categorizes the Bioidentical Hormones Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Creams & Gels, Injectable, Patches & Implants, and Tablets & Capsules.
  • Based on Hormones Type, market is studied across Estrogens, Progesterone, and Testosterone.
  • Based on End User, market is studied across Academic & Research Institutes and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing screening for hormonal deficiency
      • 5.1.1.2. Prevalence of hormonal deficiency in the population
      • 5.1.1.3. Rise in geriatric population
    • 5.1.2. Restraints
      • 5.1.2.1. Varying side effects such as blurred vision or risk of breast cancer and heart attack
    • 5.1.3. Opportunities
      • 5.1.3.1. Concentration of major research companies in the developed countries
      • 5.1.3.2. Formulation of customized hormonal therapy for specific patients
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of quality control on purity and safety of the product compared to synthetic hormone products
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bioidentical Hormones Market, by Product

  • 6.1. Introduction
  • 6.2. Creams & Gels
  • 6.3. Injectable
  • 6.4. Patches & Implants
  • 6.5. Tablets & Capsules

7. Bioidentical Hormones Market, by Hormones Type

  • 7.1. Introduction
  • 7.2. Estrogens
  • 7.3. Progesterone
  • 7.4. Testosterone

8. Bioidentical Hormones Market, by End User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Hospitals & Clinics

9. Americas Bioidentical Hormones Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bioidentical Hormones Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bioidentical Hormones Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Bayers AG
  • 3. Biote Medical, LLC
  • 4. Defy Medical, LLC
  • 5. Full Life Wellness Center
  • 6. Merck KGaA
  • 7. NextGenRx Compounding Pharmacy
  • 8. Novartis AG
  • 9. Noven Pharmaceuticals, Inc. Hisamitsu Group
  • 10. Novo Nordisk A/S
  • 11. Nueva Aesthetics
  • 12. Optimal Health and Wellness
  • 13. Pavilion Compounding Pharmacy, LLC
  • 14. Pellecome, LLC
  • 15. Pfizer Inc.
  • 16. Schwietermans Pharmacy
  • 17. The Biostation
  • 18. TherapeuticsMD, Inc.

LIST OF FIGURES

  • FIGURE 1. BIOIDENTICAL HORMONES MARKET RESEARCH PROCESS
  • FIGURE 2. BIOIDENTICAL HORMONES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BIOIDENTICAL HORMONES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BIOIDENTICAL HORMONES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOIDENTICAL HORMONES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOIDENTICAL HORMONES MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY CREAMS & GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PATCHES & IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY TABLETS & CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ESTROGENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PROGESTERONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY TESTOSTERONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM BIOIDENTICAL HORMONES MARKET SIZE, BY HORMONES TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. BIOIDENTICAL HORMONES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. BIOIDENTICAL HORMONES MARKET, FPNV POSITIONING MATRIX, 2023